Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer

被引：29
|
作者：
Merseburger, Axel S. [1 ]
Bellmunt, Joaquim [2 ]
Jenkins, Cheryl [3 ]
Parker, Chris [4 ]
Fitzpatrick, John M. [5 ,6 ]
机构：
[1] Hannover Med Sch, Dept Urol & Urol Oncol, D-30625 Hannover, Germany
[2] Univ Hosp Mar, Inst Invest Med, Med Oncol Serv, Barcelona, Spain
[3] Rocket Sci Med Commun, Wantage, Oxon, England
[4] Royal Marsden Natl Hlth Serv Fdn Trust, Sutton, Surrey, England
[5] Mater Misericordiae Hosp Univ Coll, Dept Surg, Dublin, Ireland
[6] Irish Canc Soc, Dublin, Ireland
来源：
ONCOLOGIST | 2013年 / 18卷 / 05期
关键词：
Metastatic castration-resistant; Prostate cancer; Treatment; Docetaxel; Cabazitaxel; Abiraterone acetate; Enzalutamide; CIRCULATING TUMOR-CELLS; ANDROGEN RECEPTOR GENE; MITOXANTRONE PLUS PREDNISONE; PHASE-II TRIAL; CLINICAL-TRIALS; BONE METASTASES; SIPULEUCEL-T; SKELETAL COMPLICATIONS; ABIRATERONE ACETATE; INCREASED SURVIVAL;
D O I：
10.1634/theoncologist.2012-0478
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The arrival of several new agents-cabazitaxel, abiraterone acetate, enzalutamide, and radium-223-is changing the treatment options and management of patients with metastatic castration-resistant prostate cancer (mCRPC). Many other novel agents are also being investigated. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. This review article is a summary of a European Treatment Practices Meeting, which was convened to discuss these latest data on novel agents and current treatment strategies in the mCRPC setting.
引用
收藏
页码：558 / 567
页数：10
相关论文
共 50 条
  • [1] Navigating Treatment of Metastatic Castration-Resistant Prostate Cancer: Nursing Perspectives
    dela Rama, Frank
    Pratz, Caroline
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2015, 19 (06) : 723 - 732
  • [2] Treatment of metastatic, castration-resistant prostate cancer
    von Amsberg, G.
    Merseburger, A. S.
    UROLOGE, 2020, 59 (06): : 673 - 679
  • [3] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Mostaghel, Elahe A.
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
  • [4] Monitoring of treatment for metastatic castration-resistant prostate cancer
    Hinz, Stefan
    AKTUELLE UROLOGIE, 2017, 48 (03) : 225 - 229
  • [5] Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer
    Qureshi, Zaheer
    Fatima, Eeshal
    Safi, Adnan
    Khanzada, Mikail
    Altaf, Faryal
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (04): : 206 - 214
  • [6] Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
    Rodriguez-Vida, Alejo
    Galazi, Myria
    Rudman, Sarah
    Chowdhury, Simon
    Sternberg, Cora N.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3325 - 3339
  • [7] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438
  • [8] Update on options for treatment of metastatic castration-resistant prostate cancer
    Vishnu, Prakash
    Tan, Winston W.
    ONCOTARGETS AND THERAPY, 2010, 3 : 39 - 51
  • [9] The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
    Tsao, Che-Kai
    Cutting, Elena
    Martin, Jacob
    Oh, William K.
    THERAPEUTIC ADVANCES IN UROLOGY, 2014, 6 (03) : 97 - 104
  • [10] The changing landscape in the treatment of metastatic castration-resistant prostate cancer
    El-Amm, Joelle
    Aragon-Ching, Jeanny B.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2013, 5 (01) : 25 - 40
12345